Get the Stockscreener App
97.62
0.46%
-0.419
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $97.62, with a volume of 2.03M.
It is down -0.46% in the last 24 hours and up +7.68% over the past month.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$98.04
Open:
$97.76
24h Volume:
2.03M
Relative Volume:
0.32
Market Cap:
$122.16B
Revenue:
$28.30B
Net Income/Loss:
$126.00M
P/E Ratio:
1,084.68
EPS:
0.09
Net Cash Flow:
$9.43B
1W Performance:
+0.40%
1M Performance:
+7.68%
6M Performance:
+31.88%
1Y Performance:
+31.13%
1-Day Range:
$97.09
$98.33
1-Week Range:
$96.74
$100.51
52-Week Range:
$62.07
$100.51
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
97.65 | 122.16B | 28.30B | 126.00M | 9.43B | 0.09 |
|
LLY
Lilly Eli Co
|
878.35 | 827.20B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
86.39 | 386.95B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
JNJ
Johnson Johnson
|
153.67 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
|
ABBV
Abbvie Inc
|
192.03 | 341.01B | 56.33B | 4.28B | 15.62B | 2.40 |
|
MRK
Merck Co Inc
|
88.00 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
RNC Capital Management LLC Sells 190,748 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Leo Wealth LLC Has $1.08 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences (NASDAQ:GILD) Hits New 1-Year HighWhat's Next? - MarketBeat
Gilead Sciences Target of Unusually Large Options Trading (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by abrdn plc - MarketBeat
Columbus Macro LLC Purchases 9,004 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Lazari Capital Management Inc. Cuts Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
943,628 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Jennison Associates LLC - MarketBeat
Will Gilead's twice-yearly injection dominate the HIV PrEP market? GSK doesn’t think so - FiercePharma
3 Top AI-Powered Biotech Stocks to Buy in February - The Motley Fool
Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics - Yahoo Finance
Vision Capital Management Inc. Decreases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Stratos Wealth Partners LTD. - MarketBeat
Concord Asset Management LLC VA Increases Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Discovering a Breakthrough: Gilead’s Long-Standing Commitment to Helping Change the Course of HIV - Gilead Sciences
Is Gilead Sciences (GILD) the Best Wide Moat Stock to Invest In? - Insider Monkey
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Money Concepts Capital Corp - MarketBeat
Alpha Omega Wealth Management LLC Reduces Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew D. Dickinson Sells 142,180 Shares - MarketBeat
Pharma Supply Chain Decarbonization Consortium Signs 10-Year Clean Energy Deals for Haleon, GSK, Thermo Fisher, Gilead - ESG Today
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Yahoo Finance
Deutsche Bank Adjusts Price Target on Gilead Sciences to $80 From $73 -February 04, 2025 at 09:18 am EST - Marketscreener.com
Cullinan Associates Inc. Trims Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences (GILD) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
BTC Capital Management Inc. Sells 17,282 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Foster & Motley Inc. Grows Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Cibc World Market Inc. Sells 64,941 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Concord Wealth Partners Purchases 6,194 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead: Strong Sales Growth Remains With Veklury And Beyond (NASDAQ:GILD) - Seeking Alpha
Gilead Sciences Stock: Is Wall Street Bullish or Bearish? - Nasdaq
Gilead Sciences' (GILD) Sector Perform Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Marginal Zone Lymphoma Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC, Hutchison Med - Barchart
Gilead Sciences Stock: Is Wall Street Bullish Or Bearish? - Barchart
Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Milestone Asset Management LLC - MarketBeat
Valley National Advisers Inc. Sells 9,062 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by McAdam LLC - MarketBeat
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
SteelPeak Wealth LLC Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Clear Creek Financial Management LLC Acquires Shares of 12,702 Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Mediolanum International Funds Ltd Has $5.32 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Baader Bank Aktiengesellschaft Purchases 7,328 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Synergy Asset Management LLC - MarketBeat
Abel Hall LLC Sells 2,728 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Truvada Lawsuit | Settlements for HIV Med Side Effects [2025] - Sokolove Law News & Blog
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Caprock Group LLC - MarketBeat
Forsta AP Fonden Sells 5,300 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Twelve Points Wealth Management LLC Acquires New Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Union Bancaire Privee UBP SA Purchases Shares of 16,732 Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts - Benzinga
Manning & Napier Advisors LLC Has $30.13 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gilead Sciences Inc Stock (GILD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dickinson Andrew D | Chief Financial Officer |
Jan 31 '25 |
Sale |
97.22 |
142,180 |
13,822,740 |
129,873 |
1.00%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):